Recent evidence suggests that K17 is upregulated in various types of tumors, including oral cancer, non-small cell lung cancer, basal cell carcinoma and cervical cancer, and when overexpressed, K17 acts as an oncogene (8–11). This evidence concerns the gene KRT17 and basal cell carcinoma.